Enquiry Now
Loading...
| A01035 | Pages: NA | Aug 2021 | 2141 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Asia Pacific RNA-Based Therapeutics Market- Opportunities and Forecasts, 2014 - 2022
Request Now !The RNA-based therapeutics involves broad range of the RNA-based technologies, which help the patients to diagnose or treat various chronic diseases. The RNA-based therapeutics play a crucial role in providing the accurate and precise healthcare treatments, which helps in treating the disease at molecular and sub-molecular levels. RNA-based therapeutic modalities provide beneficial business opportunities due to its rising acceptance, technological advancements and targeted drug delivery of these therapeutics as compared to the other treatment modalities (synthetic therapeutics). The Asia-Pacific RNA-based therapeutics market is growing at a promising CAGR due to the gene silencing potential of these therapeutics. However, the market is still at the nascent stage in developing regions such as India and witnessing the lucrative growth rate during the analysis period. Factors that would fuel the market growth in Asia-Pacific region are target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, high cost coupled with the high failure rates and reimbursement issues related with the adoption of RNA-based therapeutics would restrain the market growth.
The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end user and geography. Based on technology, the market is segmented into enabling technologies, enabled technologies and RNA antisense technologies. Owing to the applications, the market is segmented into cardiovascular diseases, kidney diseases, oncology infectious diseases and metabolic disorders. Based on the end users, the market is categorized into diagnostic, therapeutic and research organizations. Geographically, the market is segmented into China, Japan, India, Australia and others. Emerging economies such as India, China, Singapore and Malaysia are the potential geographies for market expansion due to improving healthcare standards. These economies have a large presence of domestic manufacturers of RNA-based therapeutics, which contribute to an increase in the market competition for multinational giants by adopting the strategy of price penetration.
Companies profiled in this report are Genzyme Corporation, Tekmira Pharmaceuticals Corp, Biocon ltd, Nitto Denko Corporation, Alnylam Pharmaceuticals, Inc. Acorda Therapeutics Inc., Arrowhead Research Corporation, Abingworth Life Science, Silence Therapeutics PLC, AstraZeneca Inc., and Catalyst Biosciences.
KEY BENEFITS
The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end users and geography segments.
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
